How a Clinical-Stage Biotech Accelerated Secure Clinical Trial Data Sharing 80% Faster with TrialAssure 

The following secure clinical data sharing case study is based on real work conducted between TrialAssure and one of its trusted sponsor partners.

Problem

A clinical-stage biotech company sought to share their clinical trial datasets voluntarily with research partners for secondary analyses and derivative research. However, they faced significant challenges, including the high risk of re-identification due to a small patient population that makes traditional qualitative anonymization insufficient. Additionally, they needed to protect patient privacy while preserving the data’s utility for meaningful research, as well as maintain compliance with varying global regulatory requirements.  

To address these complexities, they sought an experienced partner capable of delivering quantitative, evidence-based anonymization. 

Solution

TrialAssure, with its AI-powered platform ANONYMIZE, was selected as the ideal partner to meet these challenges. Leveraging over a decade of experience in clinical data transparency and anonymization, TrialAssure delivered a comprehensive solution tailored to their needs, starting with a risk-based anonymization approach. 

TrialAssure ANONYMIZE employed a sophisticated quantitative anonymization strategy to achieve measurable re-identification risk thresholds while maintaining optimal data utility. Through TrialAssure’s quick and efficient processes, the end-to-end project, encompassing risk analysis, anonymization, and reporting, was completed approximately 80 percent faster.  

On top of the anonymized dataset, TrialAssure provided a detailed Data Anonymization Report and Data Specification Report to ensure visibility into the anonymization process, support informed decision-making, and demonstrate compliance with regulatory standards. Additionally, TrialAssure ANONYMIZE acted as a secure data exchange platform, enabling seamless and protected data sharing with the clinical-stage biotech’s research partners. 

“It was a great pleasure working with the TrialAssure team, completing the project in time and with high confidence on the data compliance. Your team has delivered exceptionally professional service. I’ll definitely recommend TrialAssure if I know any others who are looking for similar support!”

Sr. Director of Biostatistics

Results

This entire project, including Quantitative Risk Analysis, Variable-Level Anonymization Strategy, and Post-Anonymization Risk Assessment, was completed within an accelerated 1-week timeline—a process that would have taken significantly longer using manual methods.  

By automating key steps, TrialAssure significantly reduced the time and resources required, providing optimal value and cost savings to the clinical-stage biotech. The company achieved measurable re-identification risk thresholds with statistical confidence, ensuring robust patient privacy and regulatory compliance. Following the success of this project, they continue to partner with TrialAssure for their secure clinical trial data sharing needs, supporting ongoing voluntary data sharing initiatives. 

Why secure clinical data sharing is harder in small populations

Small patient populations are the hardest case for anonymization. When only a handful of participants share a rare diagnosis, an age band, and a country of enrollment, stripping the obvious identifiers still leaves combinations of variables that can single someone out. Rule-based redaction cannot show how much of that risk survives—it can only show what was removed.

Quantitative anonymization answers the question directly. Risk is measured before anything is changed, each variable is treated according to how much it contributes to that risk, and the residual risk is measured again against an agreed threshold. The same logic underpins the expert determination route in the U.S. HHS de-identification guidance, where a dataset is judged on demonstrated, documented risk rather than on a fixed list of fields to strip.

Measuring risk also makes the trade-off with utility visible. A sponsor can see what a lower threshold costs in analytical value and choose deliberately, instead of over-redacting a dataset until it can no longer answer the research question it was shared to answer. That evidence is what the anonymization and specification reports carry: a receiving research partner can see how the risk was measured and what was changed, rather than taking either on trust.